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The Gram-negative bacterium Burkholderia mallei causes rapidly fatal illness in equines and humans when contracted by inha-
lation and also has the potential to be used as a bioweapon. However, little is known regarding the early innate immune re-
sponses and signaling mechanisms required to generate protection from pneumonic B. mallei infection. We showed previously
that monocyte chemoattractant protein 1 (MCP-1) was a critical chemokine required for protection from pneumonic B. mallei
infection. We have now extended those studies to identify key Toll-like receptor (TLR) signaling pathways, effector cells, and
cytokines required for protection from respiratory B. mallei infection. We found that MyD88/mice were highly susceptible to
pulmonary challenge with B. mallei and had significantly short survival times, increased bacterial burdens, and severe organ
pathology compared to wild-type mice. Notably, MyD88/mice had significantly fewer monocytes and dendritic cells (DCs) in
lung tissues and airways than infected wild-type mice despite markedly higher bacterial burdens. TheMyD88/mice were also
completely unable to produce gamma interferon (IFN-) at any time points following infection. In wild-type mice, NK cells were
the primary cells producing IFN- in the lungs following B. mallei infection, while DCs and monocytes were the primary cellu-
lar sources of interleukin-12 (IL-12) production. Treatment with recombinant IFN- (rIFN-) was able to significantly restore
protective immunity inMyD88/mice. Thus, we conclude that the MyD88-dependent recruitment of inflammatory monocytes
and DCs to the lungs and the local production of IL-12, followed by NK cell production of IFN-, are the key initial cellular re-
sponses required for early protection from B. mallei infection.
Burkholderia mallei, an obligate mammalian pathogen foundprimarily in equidae, and B. pseudomallei, an opportunistic
soil bacterium that infects a wide variety of mammalian species,
are both pathogens of mammals (7, 27). Both organisms have
been classified as category B select agents by the Centers for Dis-
ease Control and Prevention, and respiratory inoculation with
either of these bacteria elicits rapidly fatal pneumonia and sepsis
(7, 13, 22, 34). One unusual feature of Burkholderia infection is
that acute infection is rarely fully cleared but often instead results
in chronic infection with dissemination to the liver and spleen,
which inmice is typically fatal over a period of severalmonths (15,
29). Other relatively nonpathogenic species of Burkholderia in-
clude B. thailandensis and B. cenocepacia, both of which are envi-
ronmental organisms. The former may cause disease in mice after
very-high-dose inoculation (18), while B. cenocepacia causes in-
fections primarily in humans with altered pulmonary defenses,
such as patients with cystic fibrosis (16).
The role of Toll-like receptor (TLR) signaling in the host de-
fense againstBurkholderia infection has been previously examined
in a limited number of B. pseudomallei infection studies (33, 36).
TLR2was shown to actually be detrimental to the host response to
B. pseudomallei infection, and similar results were observed fol-
lowing B. thailandensis infection (33, 35). In contrast, TLR4 was
found to be nonessential for protection against B. pseudomallei or
B. thailandensis infections, and TLR5 was not essential for protec-
tion against respiratory B. thailandensis infection (32, 35). None-
theless, mice lacking myeloid differentiation factor 88 (MyD88)
are highly susceptible to infectionwith eitherB. pseudomallei orB.
thailandensis (33, 36).
Following B. pseudomallei infection, it has been reported that
gamma interferon (IFN-) production and monocyte recruit-
ment to the lungs were equivalent in wild-type (WT) and
MyD88/ mice (36). MyD88/ mice were found to produce
less tumor necrosis factor alpha (TNF-), CXC ligand 1 (KC), and
monocyte chemoattractant protein 1 (MCP-1) thanwild-type an-
imals in response to B. pseudomallei infection and were unable to
recruit neutrophils to the lungs (36). Equivalent numbers of
monocytes and neutrophils were recruited to the lungs of wild-
type and MyD88/ mice in a B. thailandensis infection model
(33). In contrast, MyD88/mice were actually protected against
respiratory infection with B. cenocepacia compared to wild-type
animals. Thus, there appear to be clear Burkholderia species-
specific differences in the host innate immune response to infec-
tion.
The production of IFN- is critical for protection from infec-
tion with B. mallei or B. pseudomallei, and TNF- production is
also required for protection from B. pseudomallei infection (1, 23,
24). We reported recently that MCP-1 (CCL2) played a key pro-
tective role in the innate immune responses to acute pulmonary
infection with B. mallei (10). In that report, we found that both
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CCR2/ and CCL2/ mice were highly susceptible to pulmo-
nary challenge with B. mallei. One key finding from those studies
was that while the CCR2/ mice had the expected defects in
monocyte recruitment, CCR2/ animals actually recruited sig-
nificantly more neutrophils and produced higher concentrations
of TNF- thanwild-type animals. These findings are in contrast to
a previous report suggesting a key protective role for neutrophils
in B. pseudomallei infection (8). Therefore, important differences
appear to exist between Burkholderia species with regard to the
necessity of MyD88 signaling for protective innate immunity.
Since the role of TLR signaling in protection from B. mallei infec-
tion has not been previously examined, we used the B. mallei lung
infection mouse model to investigate the role of MyD88 and cel-
lular and cytokine responses required to generate early protective
pulmonary immunity against this important bacterial pathogen.
MATERIALS AND METHODS
Mice. C57BL/6 mice and TLR2/ mice on the C57BL/6 background
were purchased from Jackson Laboratories (Bar Harbor, ME). To inves-
tigate the role of TLR4, theC57BL/10ScNJ strain, which contains a natural
deletion of the TLR4 gene, and control strain C57BL/10ScSnJ were used
(Jackson Laboratories). MyD88/ mice on the C57BL/6 background
were obtained from Laurel Lenz (National Jewish Medical, Denver, CO)
andwere bred in-house. All mice used in experiments were 6 to 8 weeks of
age at the time of infection, and age- and sex-matched wild-type controls
were used for all experiments employing knockout mice. All experiments
involving animals were approved by the Institutional Animal Care and
Use Committee at Colorado State University.
Bacterial strains and infections. Burkholderia mallei strain ATCC
23344 was used in these studies and was kindly provided by Herbert
Schweitzer, Colorado State University. The B. mallei organism used in
these studies was initially serially passaged three times in BALB/c mice,
and stocks were then prepared and frozen at 80°C, as described previ-
ously (11). Prior to each challenge study, fresh broth cultures of B. mallei
were grown in brucella broth with 4% glycerol (BB4G) (Remel, Lenexa,
KS) until bacteria reached the log phase of growth. Titers were determined
based on optical density values, and appropriate bacterial dilutions were
prepared in sterile phosphate-buffered saline (PBS). Inoculum titers for
each experiment were confirmed by plating the inoculumonto BB4G agar
plates (Remel).
For intranasal (i.n.) inoculation, mice were anesthetized by intraper-
itoneal (i.p.) injection with ketamine (100mg/kg of body weight) (Vedco,
Saint Joseph, MO) and xylazine (10 mg/kg) (Ben Venue Labs, Bedford,
OH). Mice were infected i.n. with a total volume of 20 l of bacterial
inoculum (10 l per nostril). The 50% lethal dose (LD50) following i.n.
infection of C57BL/6mice with B. malleiwas previously determined to be
8.4  102 CFU according to the Reed-Muench method (11, 21). Mice
were infected either with 500 CFU i.n. (0.5 LD50) or with an experi-
mentally determined LD100 of 3  103 CFU (4 LD50). In experiments
where a consistently lethal infection was necessary, mice were infected
with 1 104CFU i.n. (10 LD50). All procedures involvingB.malleiwere
performed in a biosafety level 3 (BSL3) facility, in accordance with ap-
proved BSL3 and select-agent protocols.
Determination of bacterial burden. At 24, 48, or 72 h after infection,
mice were euthanized, and halves of each lung, liver, and spleen were
collected separately and placed into 5ml sterile PBS. Organs were homog-
enized by using a Stomacher 80 Biomaster instrument (Seward, Bohemia,
NY), and supernatants were serially diluted in PBS and plated onto BB4G
agar plates (Remel). Agar plates were incubated at 37°C for 48 h, and
colonies were counted. The limit of detection for the determination of the
bacterial burden in organ homogenates was 100 CFU/organ. For the
quantification of bacteremia, heparinized blood was serially diluted in
sterile PBS andplated ontoBB4Gagar plates. The limit of detection for the
determination of the bacterial burden in the blood was 10 CFU/ml.
Histological analysis. Lungs were inflated with 10% neutral buffered
formalin (NBF) (Sigma-Aldrich, St. Louis, MO) via the trachea for 5 min
prior to removal and then placed into NBF for 24 h. Livers were collected
immediately after euthanasia and placed into NBF for 24 h. After 24 h,
organs were transferred into a solution of 70% ethanol for 7 days. Tissues
were then embedded in paraffin, sectioned, and stained with hematoxylin
and eosin. Tissues were examined and photographed by a veterinary pa-
thologist experienced in mouse pathology.
Tissue processing and immunostaining for flow cytometry analysis.
Airway cells were obtained by bronchoalveolar lavage (BAL) as previously
described (10). Cells were recovered from the BAL fluid by centrifugation.
Following lavage, lung digestion was performed as previously described
(9). Briefly, lungs were minced and digested in Hanks’ balanced salt solu-
tion (HBSS) containing 2.5 mg/ml collagenase, 10 U/ml DNase, and 10
g/ml soybean trypsin inhibitor (all reagents from Sigma-Aldrich, St.
Louis, MO). After digestion, cells were triturated through an 18-gauge
needle and passed through a 70-m cell strainer (BD Biosciences). Red
blood cells were lysed by using ammonium chloride, and cells were
washed twice in HBSS, immunostained, and then stored on ice until anal-
ysis. All cells were resuspended in fluorescence-activated cell sorter
(FACS) buffer (PBS with 2% fetal bovine serum [FBS] and 0.05% sodium
azide) before immunolabeling and flow cytometric analysis.
Directly conjugated antibodies for flow cytometry were purchased
from eBioscience (San Diego, CA) or BD Biosciences (San Jose, CA). The
following eBioscience antibodies were used for flow cytometry staining:
anti-CD11b (allophycocyanin [APC] conjugated; clone M1/70), anti-
CD11c (phycoerythrin [PE] conjugated; clone N418), anti-CD45 (Pacific
blue conjugated; clone 30-F11), anti-NK-1.1 (biotin conjugated; clone
PK136), anti-CD4 (PE conjugated; clone GK1.5), and anti-CD8 (APC
conjugated; clone 53-6.7) antibodies. The following BD Biosciences anti-
bodies were used: anti-Ly6C (biotin conjugated; clone AL-21) and anti-
Ly6G (fluorescein isothiocyanate [FITC] conjugated; clone 1A8) antibod-
ies. Pacific orange and Alexa 488 streptavidin conjugates were purchased
from Invitrogen (Carlsbad, CA). Before staining, nonspecific antibody
binding was blocked by the addition of FACS block, consisting of normal
mouse serum (Jackson ImmunoResearch, West Grove, PA), human IgG
(Jackson ImmunoResearch), and unlabeled anti-mouse CD16/32
(clone 93; eBioscience), for 5 min at room temperature. Staining was
performed with FACS buffer for 30 min on ice, followed by washing with
FACS buffer. In the case of biotinylated antibodies, the streptavidin-
fluorochrome conjugate was added next for 20 min on ice. After a final
wash, the cells were fixed in 1% paraformaldehyde in PBS for 24 h at 4°C,
washed once, resuspended in FACS buffer, and stored at 4°C until analy-
sis. Flow cytometry was performed by using a Cyan ADP flow cytometer
running Summit software (Beckman Coulter, Fullerton, CA). Analysis of
flow cytometry data was performed by using FlowJo software (Tree Star
Inc., Ashland, OR). Samples were gated on forward-scatter (FSC) and
side-scatter (SSC) characteristics for viable cells. For the investigation of
monocytes (Mono), neutrophils (polymorphonuclear leukocytes
[PMNs]), dendritic cells (DCs), and alveolar macrophages (AVM), live
cells expressing CD45 were used for analysis. Alveolar macrophages were
defined as CD11chi and CD11b cells. Dendritic cells were defined as
CD11cCD11b cells. Neutrophils were defined asCD11bLy6G cells,
while monocytes were defined as CD11b Ly6C cells that were Ly6G.
For the investigation of natural killer (NK) andT cells, live cells were gated
on lymphocytes based on their low-FSC and -SSC characteristics. NK cells
were identified as CD45 and NK 1.1 cells, and T cells were identified as
cells with low-FSC/SSC characteristics expressing CD4, CD8, or CD3.
Intracellular cytokine staining. Intracellular cytokine staining was
performed as described previously (8). Lungswereminced anddigested in
HBSS containing 0.4 mg/ml collagenase (Liberase TL; Roche, Indianapo-
lis, IN) and 10 g/ml DNase (Sigma-Aldrich) for 30 min at 37°C. After
digestion, cells were triturated through an 18-gauge needle and passed
through a 70-m cell strainer (BD Biosciences), and red blood cells were
lysed by using ammonium chloride. Following digestion, lung cells were
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cultured at 37°Cwith 5%CO2 for 4 h in RPMI 1640medium (Invitrogen)
containing 10% fetal bovine serum (Gemini Bio-Products, West Sac-
ramento, CA), 2 mM L-glutamine (Invitrogen), 0.1 mM nonessential
amino acids (Invitrogen), 0.075% sodium bicarbonate (EMD Science,
Gibbstown, NJ), 100 units/ml penicillin and 100g/ml streptomycin (In-
vitrogen), 50 M 2-mercaptoethanol (Invitrogen), and 10 g/ml brefel-
din A (BioLegend, San Diego, CA). Cells were washed in FACS buffer and
resuspended in FACS block to prevent nonspecific staining. Cells were
surface immunostained for 30 min at room temperature. In addition to
the surface antibodies described above, anti-CD11c (APC conjugated;
clone N418), anti-F4/80 (APC conjugated; clone BM8), anti-CD3 (APC
conjugated; clone 145-2C11), and anti-CD4 (FITC conjugated; clone
GK1.5) antibodies were purchased from eBioscience. Anti-CD45 anti-
body (Pacific orange conjugated; clone 30-F11) was purchased from In-
vitrogen, and anti-CD11b antibody (Alexa 700 conjugated; clone M1/70)
was purchased from BioLegend. For the detection of biotinylated anti-
bodies, cells were washed in FACS buffer and incubated with streptavidin
peridinin chlorophyll protein (PerCP) (BD Biosciences) for 20 min at
room temperature. Next, cells were washed with FACS buffer, resus-
pended in fixation-permeabilization buffer (eBioscience), and incubated
at 4°C overnight. Cells were washed in permeabilization buffer (eBiosci-
ence) and resuspended in anticytokine antibodies. Anti-interleukin-
12(p40/p70) [IL-12(p40/p70)] (PE conjugated; clone C15.6), anti-IFN-
(PE conjugated; clone XMG1.2), and rat IgG1 isotype (PE conjugated;
clone R3-34) antibodies were obtained from BD Biosciences, and anti-
TNF- (PE conjugated; clone MP6-XT22) and rat IgG1 isotype (PE con-
jugated; clone eBRG1) antibodies were obtained from eBioscience. Next,
cells were washed in permeabilization buffer and then washed in FACS
buffer. Finally, cells were fixed in 1% paraformaldehyde for 1 h at 4°C,
washed, and stored in FACS buffer until analysis. Flow cytometry was
performed, and data were analyzed as described above. Cell populations
were differentiated as described above. Additionally, F4/80 macrophages
were defined as CD45/F4/80.
Assessment of cytokine production in plasma and organ homoge-
nates. Plasma was collected in tubes coated with EDTA (BD Biosciences,
San Jose, CA). Plasmawas isolated from the blood by the centrifugation of
Microtainer tubes at 10,000  g for 5 min at 4°C. Plasma was sterile
filtered and frozen at80°C until analysis. Lung, liver, and spleen tissues
were processed as described above for the determination of the bacterial
burden. Half of each organwas placed into 5ml PBS and homogenized on
the Stomacher 80 Biomaster instrument (Seward). The homogenate was
centrifuged at 3,000 g for 15 min at 4°C, and supernatants were sterile
filtered and frozen at80°C until analysis.
Plasma and organ homogenates from wild-type and MyD88/mice
were assayed for the production of CCL2 (MCP-1), IFN-, TNF-, IL-6,
and IL-12p70 by using a cytometric bead array (CBA) (BD Biosciences).
Concentrations of CXCL1 (KC) were measured by using a commercially
available enzyme-linked immunosorbent assay (ELISA) (DuoSet kit;
R&D Systems, Minneapolis, MN) according to the manufacturer’s direc-
tions. Data acquisition from CBA experiments was performed by using a
FACScan flow cytometer andCell Quest software (BDBiosciences). Anal-
ysis of CBA data was performed by using FlowJo software (Tree Star,
Ashland,OR). For ELISAs, absorbance readingswere determined byusing
a Multiskan Ascent ELISA plate reader and Ascent software (Thermo
Scientific, Waltham, MA).
In vivo treatment with recombinant IFN-. MyD88/ mice were
injected i.p. with either 1 105 units of recombinant murine IFN- (Pe-
protech, RockyHill, NJ) or diluent (PBS plus 0.1%bovine serum albumin
[BSA]). IFN- treatments were initiated at the time of infection and con-
tinued once daily for 5 days following infection. This treatment protocol
was adapted from a protocol used previously for a Salmonella infection
model (17).
Statistical analysis. Statistical analyses were performed by using
Prism 5.0 software (Graph Pad, La Jolla, CA). Survival times were ana-
lyzed by Kaplan-Meier analysis, followed by the log rank test. Analyses
between two groups were performed by using a two-tailed Student t test.
Comparisons between 3 or more groups were performed by using one-
way analysis of variance (ANOVA) followed by Tukey’s multiple-means
test. Correlation analysis of bacterial burden and cytokine productionwas
performed by using Pearson’s correlation coefficient. Differences were
considered statistically significant at a P value of0.05.
RESULTS
MyD88/ mice are highly susceptible to Burkholderia mallei
infection. Previous studies have revealed that MyD88 signaling
plays very different roles in protective immunity from infec-
tion with different Burkholderia species. For example, MyD88-
dependent immune responses were found previously to be detri-
mental in the host response to B. cenocepacia infection, whereas
MyD88was critical for protective immunity against infectionwith
B. pseudomallei and B. thailandensis (30, 33, 36). Thus, it was un-
clear based on the published literature exactly what role MyD88
signaling might play in the innate immune response to acute
pneumonic infection with B. mallei.
Therefore, wild-type C57BL/6 mice and MyD88/ mice on
the C57BL/6 background (n 5mice per group) were inoculated
with a low i.n. challenge dose ofB.mallei (0.5 LD50; approximately
500 CFU B. mallei). Infected wild-typemice all survived to at least
day 60, whereasMyD88/mice were euthanized at an average of
3.5 days following challenge (Fig. 1).
TLR2 signaling increases susceptibility of mice to lethal B.
mallei infection. Previous studies indicated that TLR2 signaling
actually increases the susceptibility of mice to B. pseudomallei and
B. thailandensis infection (33, 35). Therefore, we conducted ex-
periments with TLR2/ mice to elucidate the role of TLR2 in
protection from B. mallei infection.Wild-type and TLR2/mice
on the C57BL/6 backgroundwere infected with an experimentally
determined LD100 (3  103 CFU; 4 LD50) of B. mallei, delivered
i.n. As reported previously, following B. pseudomallei or B. thai-
landensis infection, we found that TLR2/mice were resistant to
infection with B. mallei compared to wild-type mice (Fig. 2) (33,
35). Protection could, however, be overcome by challenge with a
higher dose of B. mallei. For example, when TLR2/ mice were
challenged with 4  103 CFU B. mallei, survival was reduced to
60% (data not shown). In addition, bacterial burdens were deter-
mined for wild-type mice (n  2) and TLR2/ mice (n  7)
surviving acute disease. At day 30 or 60 following i.n. infection, we
found that TLR2/ mice had significantly fewer bacteria in the
FIG 1 Susceptibility of MyD88/ mice to respiratory B. mallei infection.
Wild-type and MyD88/mice (n 5 per group) were infected intranasally
(i.n.) with 500 CFU B. mallei. Mice were monitored for survival and eutha-
nized upon reaching a predetermined endpoint. Statistical differences were
determined by using Kaplan-Meier curves and log rank analysis. Data are
representative of two independent experiments.
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spleen (P 0.03) than wild-type mice (data not shown). In addi-
tion, therewere no significant differences in bacterial counts in the
blood (P 0.50), and bacterial burdens in the lung and liver were
below the limit of detection for all mice (data not shown). There-
fore, we concluded that TLR2/mice not only were resistant to
acute pneumonic infection but also were protected from the de-
velopment of chronic disease.
TLR4 does not regulate resistance to pulmonary infection
with B. mallei. TLR4 is a key regulator of innate immune re-
sponses to Gram-negative bacterial infections (4, 12, 31). A recent
study found that TLR4 expression did not regulate susceptibility
toB. pseudomallei infection (35). To determinewhether TLR4was
required for protection from B. mallei challenge, wild-type and
TLR4/mice (n 5 per group) were inoculated with a low-dose
i.n. challenge of 500 CFU of B. mallei. We observed that TLR4/
mice were not more susceptible to B. mallei infection than wild-
type mice (Fig. 2). Therefore, wild-type and TLR4/ mice were
next subjected to a high-dose challenge with B. mallei (3  103
CFU;4 LD50). We found here also that TLR4/mice were not
more or less susceptible to B. mallei infection than wild-type ani-
mals (P  0.42) (data not shown). Quantification of bacterial
burden in surviving wild-type mice (n  5) and TLR4/ mice
(n 6) 30 days after i.n. infection revealed that chronic infection
developed equivalently in wild-type and TLR4/mice (data not
shown). For example, bacteria were undetectable in the lung. In
the liver, none of the wild-type mice were colonized, while 1 of 6
TLR4/mice had a liver titer of 250 CFU/organ. There were no
differences in bacterial burden observed for the spleen (P 0.87).
Therefore, we concluded that TLR4 signaling did not regulate pro-
tective immunity following pulmonary challenge with B. mallei in
mice.
MyD88/ mice have increased pulmonary and systemic
bacterial burdens associated with lung and liver pathology. The
above-described experiments indicated that MyD88/ mice
were highly susceptible to B. mallei infection. Therefore, we next
assessed bacterial burdens in MyD88/mice at several different
time points following infection. Wild-type and MyD88/ mice
(n 5 per group) were infected with a low-dose challenge of 500
CFU B. mallei delivered i.n. Mice were then euthanized at 24, 48,
or 72 h after challenge. At each time point, bacterial burdens in
blood, lung, liver, and spleen homogenates were determined.
MyD88/ mice had significantly increased bacterial burdens in
all organs at all time points after infection compared to wild-type
mice (Fig. 3).
Next, organ injury in response to B. mallei infection in wild-
type and MyD88/ mice was investigated by using histopathol-
ogy. Wild-type and MyD88/ mice (n 5 per group) were eu-
thanized on day 3.5 after infection with 500 CFU i.n. Lung and
liver tissues were fixed and routinely processed for microscopic
examination (Fig. 4). Inflammatory responses in the lungs of
MyD88/ mice were more severe than in those in the lungs of
wild-type mice. However, the pathological changes observed for
the lungs ofMyD88/mice were notably milder than the lesions
previously observed for other strains of mice that are highly sus-
ceptible to B. mallei infection, e.g., CCR2/ or IFN-/ mice
(10) (data not shown). In addition, the livers of wild-type mice
FIG 2 Susceptibility of TLR2/ and TLR4/ mice to pulmonary B. mallei
infection. (A)Wild-type andTLR2/micewere challengedwith 3 103CFU
B.mallei i.n. Survival wasmonitored, andmicewere euthanized upon reaching
a predetermined endpoint. Statistical differences were determined by using
Kaplan-Meier curves and log rank analysis. Data are representative of two
independent experiments. (B) Wild-type and C57BL/10ScNJ mice containing
a natural deletion of TLR4 (n 5 per group) were infected i.n. with 500 CFU
B. mallei. Survival was monitored, and mice were euthanized upon reaching a
predetermined endpoint. Statistical differences were determined by using
Kaplan-Meier curves and log rank analysis. Statistically similar results (P 
0.42) were obtained in a separate experiment where wild-type and TLR4/
mice were challenged with 3 103 CFU B. mallei i.n.
FIG 3 Increased bacterial burden in MyD88/mice following low-dose re-
spiratory B. mallei challenge. Wild-type andMyD88/mice were challenged
with 500 CFU B. mallei i.n. Wild-type and MyD88/ mice (n  3 to 5 per
group) were euthanized at 24, 48, or 72 h postinfection, and the bacterial
burdens in blood, lung, liver, and spleen were determined as described in
Materials andMethods. Data are expressed as mean log10 CFU/ml standard
errors of the means (SEM) for blood and mean log10 CFU/organ  SEM for
lung, liver, and spleen. Statistical differences between wild-type and
MyD88/mice at each time point were determined by Student’s two-tailed t
test (, P 0.01; , P 0.001). Data are representative of two independent
experiments.
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had small resolving lesions, whereas the lesions in MyD88/
mice were multifocal to coalescing and characterized by wide-
spread hepatocyte necrosis and leukocyte infiltration (Fig. 4). In
contrast to the lung pathology, the liver pathology in MyD88/
mice was much more severe than the liver pathology previously
seen for CCR2/ or IFN-/ mice (10) (data not shown). A
comparison of bacterial burdens between MyD88/, CCR2/,
and IFN-/mice revealed that IFN-/mice had significantly
higher bacterial burdens in both the lung and liver than
MyD88/ mice, while no significant differences were observed
betweenMyD88/ andCCR2/mice (data not shown). There-
fore, we concluded that the increased lung pathology observed for
IFN-/ mice compared to MyD88/ mice may be due to an
increased bacterial burden in IFN-/ mice. However, the dra-
matic increases in liver pathology observed for MyD88/ mice
appeared to be relatively independent of the hepatic bacterial bur-
den, as CCR2/mice had hepatic bacterial burdens equivalent to
those ofMyD88/mice yet exhibitedminimal hepatic pathology
(10) (data not shown).
Cellular recruitment to the lung is impaired in MyD88/
mice. Previous studies reported that neutrophils were critical for
the control of B. pseudomallei infection (8). In contrast, we found
instead that monocytes were critical for the control of B. mallei
infection, based on the fact that CCR2/ mice were highly sus-
ceptible to infection (10). Therefore, in the present study, we in-
vestigated the effects of TLR signaling on chemokine production
andmonocyte recruitment to the lungs ofmice followingB.mallei
inoculation. Chemokine concentrations in lung homogenates and
plasma from wild-type and MyD88/ mice (n  5 per group)
were assessed 24 h after i.n. inoculation with 500 CFU B. mallei.
The levels of production of bothCCL2 (MCP-1) andCXCL1 (KC)
were significantly reduced in MyD88/mice compared to those
of WT animals (Fig. 5).
Twenty-four hours after inoculation, airway cells were col-
lected by BAL and lung cells were obtained by enzymatic digestion
and examined by flow cytometry. In both the airways and lung
tissues of MyD88/mice, there were significantly reduced num-
bers of inflammatory cells compared to those of wild-type mice.
Notably, the numbers of CD11c CD11b DCs, Ly6Chi inflam-
matory monocytes, and neutrophils were significantly lower in
both the airways and lung tissues of infectedMyD88/mice (Fig.
6). The lack of monocyte, DC, and neutrophil recruitment was
particularly pronounced in the airways. The NK cell and CD4 T
cell populations in lung tissues were not different in MyD88/
versus wild-type mice. However, MyD88/ mice had increased
numbers of CD8 T cells (data not shown) and alveolar macro-
phages in the lungs (Fig. 6). Thus, we concluded that the recruit-
ment of key innate immune effector cells, especially inflammatory
DCs, inflammatory monocytes, and neutrophils, was MyD88 de-
pendent early after pulmonary infection with B. mallei.
Cytokineproductionby immune effector cells in the lungs in
response to B. mallei infection.Next, we conducted intracellular
cytokine production studies to identify the cellular sources of key
protective cytokines in the lungs early after B. mallei infection.
Wild-type mice (n  5) were inoculated with 104 CFU B. mallei
i.n. and euthanized 48 h after infection. Lung tissue was harvested
and processed for the detection of intracellular cytokine produc-
tion as described in Materials and Methods. Cell types producing
IL-12, IFN-, and TNF- were investigated (Fig. 7). The major
cell type producing IL-12 in the lung following B. mallei infection
was found to be a population of CD11b CD11c DCs. Smaller
amounts of IL-12were also produced by inflammatorymonocytes
FIG 4 Lung and liver pathology following respiratory B. mallei challenge in
wild-type andMyD88/mice. Mice (n 5 per group) were subjected to i.n.
challenge with 500 CFU B. mallei, and organs were collected for histological
examination 72 h later. Representative images from the lungs (top row, 20
magnification) and livers (bottom row,100magnification) of infected wild-
type and MyD88/mice are presented.
FIG 5 Chemokine production following low-dose B. mallei challenge. Wild-
type andMyD88/mice (n 5 per group)were infected i.n. with 500CFUB.
mallei. Twenty-four hours after infection, mice were euthanized, and chemo-
kine levels in lung homogenates and plasma were determined as described in
Materials and Methods. Data are presented as individual values, with bars
representing the mean concentrations for each group. Statistical differences
between wild-type and MyD88/ mice were determined by a Student two-
tailed t test (, P 0.05; , P 0.01; , P 0.001). Data are representative
of two independent experiments.
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and resident alveolar macrophages. The majority of IFN- was
produced by NK cells in the lungs, while small numbers of T cells
also expressed IFN-.
Unexpectedly, a large population of IFN- cells that did not
express NK cell or T cell markers (i.e., NK1.1/CD3) was also
observed (data not shown). We found that within this population
of cells, there were IFN-DCs,monocytes, and neutrophils (Fig.
7 and data not shown). Previous studies have demonstrated that
multiple myeloid cell types can produce IFN- following stimula-
tionwith IL-12 (3, 19). However, the remaining IFN- cells were
not identified, although we did note that they were not T cells
(data not shown).
The cellular source of TNF- production was investigated
next. We found that neutrophils were the major cellular source of
TNF- production in the lungs shortly after B. mallei infection
(Fig. 7). This finding differs from results obtained in a previously
reported B. pseudomalleimodel, wheremonocytes were identified
as the major source of TNF- production (8). We also observed
that some monocytes, dendritic cells, and alveolar macrophages
expressed TNF-.
MyD88-dependent cytokine production following B. mallei
infection. Cytokine concentrations in lung tissues and plasma
were investigated next in wild-type and MyD88/ mice follow-
ing i.n. challenge with 500 CFU B. mallei. Mice (n  5) were
euthanized 24, 48, or 72 h after infection, and cytokine concentra-
tions weremeasured in lung homogenate and plasma as described
in Materials and Methods. Compared to WT mice, MyD88/
mice had significantly reduced concentrations of TNF- in the
lung and plasma at 24 h after infection, whereas concentrations
were not different at later time points (Fig. 8). IL-12 concentra-
tions in lung tissues were below the limit of detection for both
groups of animals (data not shown). IL-6 production in the lungs
was significantly reduced in MyD88/ mice compared to WT
animals (data not shown). Remarkably, we found thatMyD88/
micewere unable to produce detectable IFN- in lung tissues or in
the circulation at any time point examined (Fig. 8). Thus, we con-
cluded that the production of IFN- following pulmonary infec-
tion with B. mallei was completely dependent on MyD88 signal-
ing, whereas the production of other key proinflammatory
cytokines (TNF and IL-6) was only partially MyD88 dependent.
The fact that bacterial burdens were very different in the lungs
of MyD88/ andWTmice could confound the interpretation of
cytokine response data. Therefore, to eliminate this potential bias,
we increased the challenge dose in WT animals to achieve equiv-
alent tissue bacterial burdens in bothWT andMyD88/ animals
(Fig. 8B). Even after achieving equivalent bacterial burdens, we
noted that the levels of production of IFN-, TNF-, and IL-6
were all significantly reduced in MyD88/ mice compared to
wild-type animals (Fig. 8C and data not shown). Interestingly,
plasma concentrations of TNF-, but not IL-6 or IFN-, were
increased inMyD88/mice at 72 h compared to wild-typemice,
with equivalent tissue bacterial burdens (Fig. 8C and data not
shown). Thus, MyD88/mice appeared to have a compensatory
mechanism for the systemic production of TNF- in response to
i.n. B. mallei infection.
Since adjusting bacterial challenge doses to achieve equal bac-
terial burdens is time-consuming and expensive, we investigated
whether it was possible to adjust cytokine concentrations simply
based on the bacterial burden. The validity of this assumption was
explored by determining whether there was a significant correla-
FIG 6 Cellular inflammation in the lung is reduced in MyD88/ mice following intranasal B. mallei challenge. Wild-type and MyD88/ mice (n  5 per
group) were infected i.n. with 500 CFU B. mallei. Twenty-four hours after infection, mice were euthanized, and BAL fluid and lung cells were isolated and
immunostained as described in Materials and Methods. Cell populations were defined as follows: dendritic cells (DCs), CD45/CD11b/CD11c; monocytes
(Mono), CD45/CD11b/Ly6-C/Ly6G; neutrophils (PMN), CD45/CD11b/Ly6G; alveolar macrophages (AVM), CD45/CD11c/CD11b. The per-
centage of live cells for each cell type are displayed as individual data points, with bars representing the mean values for each population isolated from the BAL
fluid (A) or lung tissue (B). Data are representative of two independent experiments. Statistical differences between wild-type and MyD88/ mice were
determined by a Student two-tailed t test. (, P 0.05; , P 0.01; , P 0.001). (C) Representative dot plots illustrating DC (top) populations as well as
Mono and PMN populations (bottom). BAL fluid dot plots were generated by using FlowJo software to pool all 5 BAL fluid .fcs files from each group. A total of
50,000 events from each pooled BAL fluid .fcs file were used to generate representative dot plots. Lung dot plots are individual samples representative of each
group. The percentage of total live cells is listed in or next to each gate. Data are representative of two independent experiments.
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tion between the cytokine concentration and bacterial burden at
different bacterial burdens. Bacterial burdens and cytokine con-
centrations were measured in the lung (n 60) and plasma (n
18) of wild-type mice infected with either 500 or 104 CFU B. mal-
lei. For the lung, we found significant correlations with bacterial
burden for CCL2, CXCL1, IL-6, and TNF- concentrations (P
0.001).However, a correlationwith IFN- concentrationswas not
observed (P  0.28). Cytokine production from wild-type and
MyD88/mice infected with 500 CFU i.n. (Fig. 8A) was mathe-
matically normalized to the bacterial burden (Fig. 8E). The nor-
malization of TNF- and IL-6 in the lung produced results con-
sistent with results obtained following a high-dose infection (Fig.
8C and data not shown). These results demonstrate that the in-
creased production of TNF- seen at 72 h (Fig. 8A) was mostly
due to an increased bacterial burden in MyD88/mice. In con-
trast, plasma concentrations did not correlate with bacterial bur-
den for any of the cytokines investigated in this study (Fig. 8D and
data not shown). Therefore, in the lung, but not the blood, the
normalization of cytokine concentrations to the bacterial burden
may be valid for the evaluation of most inflammatory cytokines
but not IFN-.
In summary, B. mallei infection induced the early production
of IFN-, TNF-, and IL-6 in both the lung and plasma of wild-
type animals, whereas concentrations were significantly reduced
inMyD88/mice. However,MyD88/mice had increased lev-
els of production of TNF- in the plasma at 72 h, which was
independent of the bacterial burden (Fig. 8C). MyD88/ mice
were, however, incapable of producing IFN- at any time point
regardless of the bacterial burden.
Recombinant IFN- treatment protects MyD88/ mice.
Therefore, we focused our attention next on the IFN- produc-
tion defect inMyD88/mice and whether IFN-was indeed the
key cytokine required for MyD88-dependent protection from B.
mallei infection. To address this question, MyD88/ mice were
treated with recombinant murine IFN- immediately after B.
mallei infection. Themicewere treated once daily with 105 units of
FIG 7 Cellular sources of IL-12, IFN-, and TNF- following respiratory B. mallei challenge. Wild-type mice (n 5) were challenged with 104 CFU B. mallei
intranasally and euthanized 48 h after infection. Lung tissue was digested and immunostained as described in Materials and Methods. Cell populations were
defined as follows: dendritic cells (DCs), CD45/CD11b/CD11c; monocytes (Mono), CD45/CD11b/Ly6-C/Ly6G; neutrophils (PMN), CD45/
CD11b/Ly6G; alveolar macrophages (AVM), CD45/CD11b/CD11c; natural killer (NK) cells, CD45/NK1.1; T cells, low FSC/SSC/CD3. Cellular
sources of IL-12 (A), IFN- (B), and TNF- (C) are presented. Total numbers of cytokine-producing cells were calculated by subtracting isotype-positive cells
from cytokine-positive cells. Data are graphed as individual values, with bars representing the mean values for each cell type. Statistical differences were
determined by a one-way ANOVA followed by Tukey’s multiple-means test to determine differences between cell types (, P  0.01; , P  0.001).
Representative flow plots are presented for the major cell type producing each cytokine. Flow plots were generated by pooling all 5 samples into one .fcs file and
then equalizing the number of events in each pooled flow plot. Values in flow plots represent percentages of each cell type. Data are representative of two
independent experiments.
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FIG 8 Cytokine production in wild-type andMyD88/mice following respiratory B. mallei challenge. Wild-type andMyD88/mice were infected i.n. with
B. mallei. Mice were euthanized 24, 48, or 72 h after infection, and both cytokine production and bacterial burden in lung homogenates and plasma were
determined as described in Materials and Methods. (A) Cytokine production in lung and plasma of wild-type and MyD88/mice (n 5 per group) infected
i.n. with 500 CFU. (B and C) Bacterial burden and cytokine production in lung homogenates and blood of mice infected with B. mallei i.n. (wild-type mice, 104
CFU;MyD88/mice, 500CFU) (n 5 per group). (D)Correlation betweenTNF-production and bacterial burden in lung homogenates (n 60) and plasma
(n  18) of wild-type mice infected with either 104 or 500 CFU B. mallei i.n. (E) TNF- production mathematically normalized to bacterial burden in lung
homogenates and plasma of wild-type andMyD88/mice infected with 500 CFU B. mallei i.n. For panels A to C and E, data are plotted as means SEM, and
graphs are representative of two independent experiments. For panel D, individual values are plotted, and data were pooled from 2 independent experiments.
Best-fit lines in panel D illustrate the semilog regression for each data set. Statistical differences between wild-type andMyD88/mice at each time point were
determined by Student’s two-tailed t test. Correlation analysis was performed by using Pearson’s correlation coefficient (, P  0.05; , P  0.01; , P 
0.001).
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recombinant IFN- (rIFN-) administered intraperitoneally
(i.p.) as described previously for a mouse Salmonella infection
model (17). Mice (n 5) were treated with rIFN- at the time of
infection and then once daily for 5 days, while a separate group of
controlMyD88/mice (n 5) received i.p. injections of diluent.
Treatment with rIFN- provided significant, though not com-
plete, protection against respiratory B. mallei infection compared
to MyD88/mice receiving diluent (Fig. 9). Additionally, while
80%ofMyD88/mice treatedwith rIFN- cleared bacteria from
their lungs, all mice ultimately developed disseminated infection
in the spleen and liver (data not shown).
DISCUSSION
In the present study, the role of MyD88 signaling in generating
protective immunity against pulmonary challenge with B. mallei
was investigated in order to gain a better understanding of the role
of innate immunity in controlling pulmonary infection with this
important pathogen. Notably, we found that MyD88/ mice
were highly susceptible to infection with even very low intrana-
sally delivered doses ofB.mallei. Alongwith an inability to control
bacterial replication in the lungs, inflammatory responses in the
lungs ofMyD88/mice were significantly attenuated. For exam-
ple, MyD88/mice were unable to recruit inflammatory mono-
cytes, myeloid dendritic cells, or neutrophils to the lungs. In con-
trast, no differences in pulmonaryNK or CD4T cell populations
were observed, while numbers of CD8 T cells were increased in
MyD88/mice. Cytokine analysis revealed thatMyD88/mice
were completely unable to produce IFN-, while the levels of pro-
duction of TNF- and IL-6were reduced only at early time points.
Remarkably, despite the large number of immune defects ob-
served forMyD88/mice followingB.mallei infection, the treat-
ment of MyD88/ mice with only rIFN- was able to signifi-
cantly reverse their susceptibility to B. mallei infection.
Some immune responses inMyD88/mice following B. mal-
lei infection were similar to those observed previously for
MyD88/mice infected with B. pseudomallei (36). For example,
neutrophil recruitment was reduced in both infection models in
MyD88/mice.However,MyD88/mice infectedwithB.mal-
lei also exhibited significant defects in monocyte recruitment,
which was not observed previously for MyD88/ mice infected
with B. pseudomallei or B. thailandensis (33, 36). The reasons for
this difference are unclear, since MyD88/ mice infected with
any of these three Burkholderia species produce significantly less
CCL2 than wild-type animals (33, 36).
Other notable differences betweenB.mallei- andB. pseudomallei-
infected mice include differences in cell types producing TNF-.
We found that neutrophils were the major cellular source of
TNF- production in the lungs following B. mallei infection,
whereas previous studies found that monocytes were the primary
source of TNF- production following B. pseudomallei infection
(8). The reasons for these differences are unclear but could be
related to differences in the bacterial envelope (e.g., lipopolysac-
charide [LPS] or capsule) or to the bacterial burden or the timing
of sampling. In agreement with data from previous studies of B.
mallei and B. pseudomallei, IFN- was produced mainly by NK
cells (8, 14, 23).
Our previous studies with CCR2/mice indicated that IFN-
was critical for protection against B. mallei infection (10). There-
fore, the production of IL-12, which is the keymolecule regulating
the NK cell production of IFN-, was investigated following B.
mallei infection. We found that IL-12 in the lungs was produced
largely by DCs andmonocytes. Since the recruitment of both DCs
and monocytes to the lungs was significantly impaired in
MyD88/mice,we postulate that the defect in IFN-production
observed for the lungs of MyD88/ mice was due to the lack of
local IL-12 production. Our results are in accordance with previ-
ous findings from a Listeriamonocytogenes infectionmodel, which
also identifiedmonocyte-derivedDCs as themajor cellular source
of IL-12. Additionally, IL-12 production byDCs following Listeria
monocytogenes infection was found previously to be dependent on
MyD88 signaling (37).
IFN- is known to be critical for the immune response to B.
mallei infection, and inflammatory monocytes appear to be criti-
cal for the production of IFN- (10, 23). Monocytes were also
found to be critical for protection following intravenous inocula-
tion with Francisella tularensis, where MyD88/, IFN-R/,
and CCR2/mice all had defects inmonocyte recruitment to the
spleen (20). Similar to the current study, IFN- production fol-
lowing intravenous (i.v.) F. tularensis infection was also found to
be MyD88 dependent. Signaling through the IFN- receptor
(IFN-R) was necessary for CCL2 production, and CCL2 produc-
tion was necessary for monocyte recruitment. A similar TLR-
dependent signaling circuit may be occurring following B. mallei
infection of MyD88/mice.
Important differences were also identified, however, including
the fact that in the B. mallei infection model, TNF- production
remained intact in CCR2/ mice despite reduced monocyte re-
cruitment to the lung. Neutrophils were the major source of
TNF- production in B. mallei-infected mice, and TNF produc-
tion was at least partially MyD88 independent. Additionally, al-
though CCR2/ mice retained the ability to signal through
MyD88 and produce IFN- in response to TLR3-activating li-
gands, CCR2/ mice produced less IFN- following B. mallei
infection (10). These results demonstrate that additional signals,
in addition to MyD88, are necessary for the production of IFN-
following infection with B. mallei.
Although the administration of exogenous IFN- was suffi-
cient to induce a partial but significant protection of MyD88/
mice from acute disease following B. mallei infection, the protec-
tion was not complete. This finding suggests that other cytokines
may be necessary for full protection. Indeed, the levels of produc-
tion of a number of other cytokines were significantly reduced in
FIG 9 IFN- treatment protects MyD88/ mice against lethal B. mallei in-
fection. MyD88/ mice were treated i.p. with recombinant IFN- (rIFN-)
or diluent (PBS plus 0.1% BSA) (n  5 per group) as described in Materials
and Methods. Mice were challenged with 500 CFU B. mallei i.n. Survival was
monitored, and mice were euthanized upon reaching a predetermined end-
point. Statistical differences were determined by using Kaplan-Meier curves
and log rank analysis. Data were pooled from two independent experiments.
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B.mallei-infectedMyD88/mice. For example, the levels of pro-
duction of TNF-, CCL2, CXCL1, and IL-6 were all significantly
reduced at 24 h postinfection in the lungs of MyD88/ mice
compared to wild-type mice (Fig. 5 and 8 and data not shown).
Similar to previous studies with a B. thailandensis model of pul-
monary infection, we found that MyD88-independent mecha-
nisms resulted in increased cytokine production in MyD88/
mice 72 h after infection, although the extremely high bacterial
burdens in MyD88/ mice made the interpretation of cytokine
production difficult (33) (Fig. 3).
It was also noted in this study that MyD88/ mice infected
with B. mallei developed much more severe hepatic necrosis than
wild-type animals (Fig. 4). A similar effect was observed previ-
ously for MyD88/mice infected with B. pseudomallei (36). It is
possible that the high bacterial burdens in the livers ofMyD88/
mice may account for this dramatic liver pathology. However,
previous studies from our laboratory demonstrated that B. mallei
infection of CCR2/ or IFN-/mice resulted in equivalent or
increased liver bacterial burdens compared to those ofMyD88/
mice (data not shown), yet neither CCR2/ nor IFN-/mice
developed the severe liver pathology observed for MyD88/
mice (data not shown) (10, 11). Thus, we propose that an in-
creased systemic production of TNF- inMyD88/micemay be
one explanation for the accentuated liver pathology observed in
this study, likely triggered by LPS released from dead or dying
bacteria (Fig. 8) (2). Moreover, the adverse effects of LPS and
TNF- on the liver appear to be magnified by the lack of MyD88
signaling. For example, MyD88/ mice are known to have de-
fects in liver regeneration (26). Additional defects in MyD88/
mice may also contribute to liver damage, as other cytokines in
addition to TNF- are known to elicit liver damage and suppress
effective regeneration (5, 6, 25, 28).
In summary, we report here that MyD88 is a critical molecule
required for effective innate immunity against pulmonary infec-
tion with B. mallei. Interestingly, the lack of TLR2 or TLR4 signal-
ing did not recapitulate the effects of an MyD88 deficiency in our
studies. As TLR9 signaling was also reported not to play a role in
protection fromB. pseudomallei infection,mice lacking individual
TLRs do not appear to be as susceptible to Burkholderia infection
asMyD88/mice (33, 35, 36). These results suggest thatmultiple
TLRsmust be concurrently inactive to reproduce theMyD88 phe-
notype. Alternatively, TLR-independent but MyD88-dependent
signaling through the IL-1 receptor (IL-1R) or IL-18R signaling
pathways may be necessary for inducing full protection against
Burkholderia infection. The major immune defects in MyD88/
mice appear to be related to the decreased recruitment of inflam-
matory DCs and monocytes to the lungs, since these are the pri-
mary cellular sources of IL-12 production, which in turn regulates
IFN- production by pulmonary NK cells. This hypothesis is bol-
stered by the fact that simply replacing the missing IFN- by the
administration of rIFN- can largely restore effective short-term
immunity to B. mallei infection. These findings suggest that strat-
egies to enhanceDC ormonocyte recruitment to the lungs, as well
as local IL-12 production, could be effective countermeasures for
B. mallei infection. Indeed, our previous studies of mucosally de-
livered immunotherapy for Burkholderia infection suggest that
this approach can efficiently protect animals from pulmonary
challenge (11).
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